Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    0761-010
Show Display Options
Rank Status Study
1 Recruiting Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
Condition: Cutaneous T-Cell Lymphoma
Interventions: Biological: KW-0761;   Drug: Vorinostat

Indicates status has not been verified in more than two years